1. Home
  2. SWKH vs GOSS Comparison

SWKH vs GOSS Comparison

Compare SWKH & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWKH
  • GOSS
  • Stock Information
  • Founded
  • SWKH 1996
  • GOSS 2015
  • Country
  • SWKH United States
  • GOSS United States
  • Employees
  • SWKH N/A
  • GOSS N/A
  • Industry
  • SWKH Diversified Financial Services
  • GOSS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SWKH Finance
  • GOSS Health Care
  • Exchange
  • SWKH Nasdaq
  • GOSS Nasdaq
  • Market Cap
  • SWKH 201.5M
  • GOSS 237.9M
  • IPO Year
  • SWKH 1999
  • GOSS 2019
  • Fundamental
  • Price
  • SWKH $16.39
  • GOSS $0.96
  • Analyst Decision
  • SWKH
  • GOSS Strong Buy
  • Analyst Count
  • SWKH 0
  • GOSS 5
  • Target Price
  • SWKH N/A
  • GOSS $9.20
  • AVG Volume (30 Days)
  • SWKH 8.6K
  • GOSS 1.0M
  • Earning Date
  • SWKH 11-14-2024
  • GOSS 03-04-2025
  • Dividend Yield
  • SWKH N/A
  • GOSS N/A
  • EPS Growth
  • SWKH N/A
  • GOSS N/A
  • EPS
  • SWKH 0.84
  • GOSS N/A
  • Revenue
  • SWKH $24,725,000.00
  • GOSS $105,322,000.00
  • Revenue This Year
  • SWKH N/A
  • GOSS N/A
  • Revenue Next Year
  • SWKH $6.17
  • GOSS N/A
  • P/E Ratio
  • SWKH $19.54
  • GOSS N/A
  • Revenue Growth
  • SWKH N/A
  • GOSS N/A
  • 52 Week Low
  • SWKH $15.14
  • GOSS $0.50
  • 52 Week High
  • SWKH $18.49
  • GOSS $1.60
  • Technical
  • Relative Strength Index (RSI)
  • SWKH 53.54
  • GOSS 54.23
  • Support Level
  • SWKH $16.25
  • GOSS $0.83
  • Resistance Level
  • SWKH $16.64
  • GOSS $1.18
  • Average True Range (ATR)
  • SWKH 0.35
  • GOSS 0.10
  • MACD
  • SWKH 0.05
  • GOSS -0.01
  • Stochastic Oscillator
  • SWKH 78.07
  • GOSS 41.37

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Share on Social Networks: